Radiology

Synchrocyclotron for the MEVION S250i Proton Therapy System Delivered to Huntsman Cancer Institute

Wednesday, April 1, 2020 - 2:00pm

Mevion Medical Systems announced today that it has delivered the synchrocyclotron accelerator for the MEVION S250i Proton Therapy System to Huntsman Cancer Institute (HCI) at the University of Utah (U of U) on March 28, 2020.

Key Points: 
  • Mevion Medical Systems announced today that it has delivered the synchrocyclotron accelerator for the MEVION S250i Proton Therapy System to Huntsman Cancer Institute (HCI) at the University of Utah (U of U) on March 28, 2020.
  • By reducing the size and complexity of a proton therapy system, Mevion has allowed hospitals to offer proton therapy without the enormous expenditures and space requirements needed by other single-room or multi-room proton systems.
  • Today, more cancer centers are considering providing compact proton therapy to their patients because of the technology Mevion has advanced.
  • Mevion Medical Systems, Inc. is the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients.

Within Health Launches Direct Access to Radiology to Help Triage COVID-19 Hospital Surge

Wednesday, April 1, 2020 - 12:00pm

They have partnered with Zwanger-Pesiri Radiology and mobile X-ray vendors to offer New Yorkers experiencing symptoms the option to get X-rays or CT scans for rapid triage .

Key Points: 
  • They have partnered with Zwanger-Pesiri Radiology and mobile X-ray vendors to offer New Yorkers experiencing symptoms the option to get X-rays or CT scans for rapid triage .
  • Hospitals and ERs across the United States, and in particular New York, are overwhelmed by the increasing number of COVID-19 patients.
  • The surge is largely due to the lack of available testing, expensive and slow testing methods, and ineffective isolation efforts.
  • Our mission is to enable convenient, personal and affordable access to preventive health services while also providing an experience that meets the highest standards of quality and comfort.

Smart Reporting Provides Free Template to Support Radiologists in Suspected COVID-19 Cases

Tuesday, March 31, 2020 - 6:00pm

MUNICH, March 31, 2020 /PRNewswire/ --Smart Reporting, a German company and platform for enhanced medical documentation, is offering a free reporting template for radiologists.

Key Points: 
  • MUNICH, March 31, 2020 /PRNewswire/ --Smart Reporting, a German company and platform for enhanced medical documentation, is offering a free reporting template for radiologists.
  • This template provides guidance for the diagnosis of COVID-19 in computed tomography of the chest," says Prof. Dr. med.
  • Smart Reporting collaborates with an international group of experts to create a reporting template specifically designed for suspected COVID-19 cases.
  • The Smart Reporting software provides digitized decision trees that support clinicians in evaluating a specific clinical indication.

Sectra Wins Enterprise Imaging Contract at the MetroHealth System in Cleveland

Tuesday, March 31, 2020 - 1:33pm

SHELTON, Connecticut, March 31, 2020 /PRNewswire/ --International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will install the radiology and breast imaging modules of its enterprise imaging solution at MetroHealth.

Key Points: 
  • SHELTON, Connecticut, March 31, 2020 /PRNewswire/ --International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will install the radiology and breast imaging modules of its enterprise imaging solution at MetroHealth.
  • The Sectra solution, integrated with Epic Radiant, will allow workflow optimization for all radiologists and radiology residents within the health system.
  • Sectra's enterprise imaging solution provides a unified strategy for all imaging needs while lowering operational costs.
  • Sectra offers an enterprise imaging solution comprising PACS for imaging-intense departments (radiology, pathology, cardiology, orthopedics), VNA, and share and collaborate solutions.

SAB Biotherapeutics Awarded $27M Contract to Develop Novel Rapid Response Capability for U.S. Department of Defense

Tuesday, March 31, 2020 - 3:44pm

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company, advancing a new class of immunotherapies leveraging the native human immune response, announced today it has been awarded a contract from the U.S. Department of Defense (DoD) to develop and test a Rapid Response Antibody Program, valued at up to $27 million.

Key Points: 
  • SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company, advancing a new class of immunotherapies leveraging the native human immune response, announced today it has been awarded a contract from the U.S. Department of Defense (DoD) to develop and test a Rapid Response Antibody Program, valued at up to $27 million.
  • View the full release here: https://www.businesswire.com/news/home/20200331005569/en/
    SAB Biotherapeutics has a unique ability to rapidly respond to emerging threats with its proprietary human polyclonal therapeutic platform.
  • Driven by advanced genetic engineering and antibody science, SAB has developed the DiversitAb platform to naturally and rapidly produce large amounts of targeted human antibodies, without human donors.
  • Our therapies leverage the native immune response thereby providing a highly-specific match against the complexity, diversity and mutation of disease.

Echosens and MetaPhy Health Collaborate to Expand Patient-Centered Care for Chronic Liver Conditions: Gastroenterology Specialists Improve Outcomes, Lower Costs & Enhance Practice Performance

Tuesday, March 31, 2020 - 2:00pm

Many individuals with gastrointestinal issues are also living with other chronic diseases that can be improved through early detection, monitoring, patient education and engagement.

Key Points: 
  • Many individuals with gastrointestinal issues are also living with other chronic diseases that can be improved through early detection, monitoring, patient education and engagement.
  • Dr. Reed Hogan, M.D., GI Associates (GIA) in Flowood, Mississippi, says the practice has successfully integrated its FibroScan capabilities with the MetaPhy CCM programs.
  • By engaging patients in this comprehensive care program, we hope to improve patient outcomes and reduce costs, while also enhancing practice performance.
  • MetaPhy Health partners with gastroenterology practices to provide comprehensive chronic disease management services to their patient populations.

Sectra Wins Enterprise Imaging Contract at the MetroHealth System in the U.S.

Tuesday, March 31, 2020 - 7:56am

Linkping, Sweden and Shelton, CT, March 31, 2020 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B)will install the radiology and breast imaging modules of its enterprise imaging solution at MetroHealth.

Key Points: 
  • Linkping, Sweden and Shelton, CT, March 31, 2020 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B)will install the radiology and breast imaging modules of its enterprise imaging solution at MetroHealth.
  • The Sectra solution, integrated with Epic Radiant, will allow workflow optimization for all radiologists and radiology residents within the health system.
  • MetroHealth provides care to residents of Northeastern Ohio, of which 75% of visits come from the uninsured and those covered by Medicare and Medicaid.
  • Sectra's enterprise imaging solution provides a unified strategy for all imaging needs while lowering operational costs.

FDA Approves Next-Generation ZOLL® TherOx System for Widowmaker Heart Attack Patients

Monday, March 30, 2020 - 2:23pm

We are pleased to provide the interventional cardiologist with a new treatment that augments the standard of care for patients.

Key Points: 
  • We are pleased to provide the interventional cardiologist with a new treatment that augments the standard of care for patients.
  • More than 30% of severe heart attack patients develop heart failure,3 and of those, 50% will die within five years.3 SSO2 Therapy has been shown in prospective clinical trials to safely reduce infarct size in widowmaker heart attack patients5.
  • Decades of research on heart attack patients has demonstrated that infarct size reduction is correlated with reduced mortality and heart failure, and better left ventricular function.4
    SSO2 Therapy was developed by Irvine, California-based TherOx, Inc., now part of ZOLL Medical Corporation.
  • TherOx and ZOLL are trademarks and/or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries.

Cobham Advanced Electronic Solutions Space Pedigree Aids in Coronavirus Fight

Monday, March 30, 2020 - 2:00pm

Cobham Advanced Electronic Solutions (CAES) , a leading provider of mission critical electronic solutions, announced today accelerated demand for its technology to be used for rapid sequencing of coronavirus samples for analysis and to aid in diagnosing and treating coronavirus patients.

Key Points: 
  • Cobham Advanced Electronic Solutions (CAES) , a leading provider of mission critical electronic solutions, announced today accelerated demand for its technology to be used for rapid sequencing of coronavirus samples for analysis and to aid in diagnosing and treating coronavirus patients.
  • (Graphic: Business Wire)
    Developing and producing high performing electronic solutions that work the first time, every time under challenging conditions is in our DNA, said Shawn Black, CEO, Cobham Advanced Electronic Solutions.
  • Leveraging an unparalleled space pedigree, particularly in radiation hardness and high reliability, Cobham Advanced Electronic Solutions has developed innovative digital and mixed-signal ASICs that perform in the harshest environments, including medical radiology.
  • Cobham Advanced Electronic Solutions (CAES) provides a number of mission-critical and specialized solutions for harsh environments.

Intensity Therapeutics Reports Safety Results from First Cohort of the KEYNOTE A10 Combination Clinical Trial of INT230-6 and Keytruda®

Monday, March 30, 2020 - 12:35pm

Patientss tumors were treated every two weeks for 5 doses with INT230-6 in combination with 200 mg of Keytruda every three weeks.

Key Points: 
  • Patientss tumors were treated every two weeks for 5 doses with INT230-6 in combination with 200 mg of Keytruda every three weeks.
  • Following completion of the dosing of INT230-6, patients continue on Keytruda monotherapy for up to 2 years.
  • Intensity also plans a fourth phase 2 cohort to test the combination in squamous cell carcinoma patients who have already failed a PD1/PDL1 agent.
  • The confirmation of safety in our first combination cohort marks an important milestone in our evaluation of INT230-6 dosed with Keytruda, commented Lewis H. Bender , President and Chief Executive Officer of Intensity Therapeutics.